

**Supplemental TABLE 1. Studies Included in the Analysis**

Study number	Study objective	Study design	Treatment arms	Study N*	Duration
306 (NCT00072774) DeMartinis et al, 2007	Efficacy, safety in MDD	Randomized DB, placebo-controlled, fixed dose	Desvenlafaxine 100 mg/d Desvenlafaxine 200 mg/d Desvenlafaxine 400 mg/d Placebo	470	8 weeks
332 (NCT00277823) Liebowitz et al, 2008	Efficacy, safety in MDD	Randomized DB, placebo-controlled, fixed dose	Desvenlafaxine 50 mg/d Desvenlafaxine 100 mg/d Placebo	451	8 weeks
333 (NCT00300378) Boyer et al, 2008	Efficacy, safety in MDD	Randomized DB, placebo-controlled, fixed dose	Desvenlafaxine 50 mg/d Desvenlafaxine 100 mg/d Placebo	485	8 weeks
335 (NCT00384033) Tourian et al, 2009	Efficacy, safety in MDD	Randomized, DB, placebo- and comparator-controlled, fixed-dose	Desvenlafaxine 50 mg/d Desvenlafaxine 100 mg/d Duloxetine 60 mg/d Placebo	616	8 weeks
3359 (NCT00798707) Iwata et al, 2013	Efficacy, safety in MDD	Randomized, DB, placebo-controlled, fixed-dose	Desvenlafaxine 25 mg/d Desvenlafaxine 50 mg/d Placebo	699	8 weeks
3362 (NCT00863798) Liebowitz et al, 2016	Efficacy, safety in MDD	Randomized, DB, placebo-controlled, fixed-dose	Desvenlafaxine 10 mg/d Desvenlafaxine 50 mg/d Placebo	673	8 weeks
3364 (NCT01121484) Clayton et al, 2013	Efficacy, safety in MDD; perimenopausal and postmenopausal women	Randomized, DB, placebo-controlled, fixed-dose	Desvenlafaxine 50 mg/d Placebo	434	10 weeks (8-week primary end point)
4415 (NCT00824291) Dunlop et al, 2011	Efficacy, safety in MDD; functional outcomes in employed patients	Randomized, DB, placebo-controlled, fixed-dose	Desvenlafaxine 50 mg/d Placebo	427	12 weeks
1028 (NCT01432457) Clayton et al, 2015	Efficacy, safety in MDD	Randomized DB, placebo-controlled, fixed dose	Desvenlafaxine 50 mg/d Desvenlafaxine 100 mg/d Placebo	909	8 weeks

DB, double-blind; MDD, major depressive disorder.

\*Total number of patients in the safety population (all randomized patients who took at least 1 dose of study medication).